ASNS - Arsanis, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
3.1100
0.0000 (0.00%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close3.1100
Open3.2400
Bid0.0000 x 800
Ask0.0000 x 1400
Day's Range3.0506 - 3.7699
52 Week Range1.1500 - 22.4300
Volume607,244
Avg. Volume85,202
Market Cap45.542M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • GlobeNewswire2 months ago

    Consolidated Research: 2019 Summary Expectations for The Trade Desk, Aduro Biotech, Walker & Dunlop, California Resources, Century Casinos, and Arsanis — Fundamental Analysis, Key Performance Indications

    NEW YORK, Feb. 14, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • PR Newswire4 months ago

    INVESTOR ALERT: Monteverde & Associates PC is Investigating the Recently Announced Acquisition

    NEW YORK , Jan. 5, 2019 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York ...

  • GlobeNewswire4 months ago

    Report: Exploring Fundamental Drivers Behind GTT Communications, Midstates Petroleum, Arsanis, BioTelemetry, Dolby Laboratories, and Northern Dynasty Minerals — New Horizons, Emerging Trends, and Upcoming Developments

    NEW YORK, Dec. 11, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • ACCESSWIRE5 months ago

    Arsanis Shares Soar on Recent Merger Agreement, Analysts Review and Target Price

    NEW YORK, NY / ACCESSWIRE / December 3, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Arsanis, Inc. (ASNS), a clinical-stage biopharmaceutical company focused on applying monoclonal antibody (mAb) immunotherapies to address serious infectious diseases. Arsanis' pipeline is comprised of mAbs targeting multiple serious bacterial and viral pathogens, including a respiratory syncytial virus. A merger announcement involving ASNS sent the company shares soaring from $1.16 on November 26, 2018 to $4.12 per share the next day.

  • ACCESSWIRE5 months ago

    Biotech's Tackling Major Issues You Should Know

    HENDERSON, NV / ACCESSWIRE / November 29, 2018 / Here are a few biotech/ healthcare and CBD companies that require your attention. Today we are highlighting: BioRestorative Therapies, Inc. (BRTX), MedMen ...

  • ACCESSWIRE5 months ago

    Today’s Research Reports on Stocks to Watch: Arsanis and Aethlon Medical

    NEW YORK, NY / ACCESSWIRE / November 28, 2018 / Biotech stocks Arsanis and Aethlon Medical were both seeing big gains on Tuesday on positive developments. Arsanis and privately held X4 Pharmaceuticals have agreed to merge and Aethlon announced it had received Breakthrough Device designation from FDA for their Hemopurifier in the treatment of cancer.

  • ACCESSWIRE5 months ago

    SHAREHOLDER ALERT: WeissLaw LLP Investigates Arsanis, Inc.

    NEW YORK, NY / ACCESSWIRE / November 27, 2018 / WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Arsanis, Inc. ("ASNS" ...

  • ACCESSWIRE5 months ago

    The Reason Healthcare Stocks Are Being Called Home By Investors

    CORAL GABLES, FL / ACCESSWIRE / November 27, 2018 / Healthcare stocks helped boost the stock market rally on Monday. Recently concluded mid-term elections have provided a much-needed boost to the healthcare sector. New trends that the majority of healthcare companies are working on are also boosting the sector.

  • GlobeNewswire5 months ago

    Arsanis and X4 Pharmaceuticals Agree to Merger

    Arsanis, Inc. (ASNS) and privately-held X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics designed to improve immune cell trafficking to treat rare diseases and cancer, today announced that they have entered into a definitive merger agreement under which X4 Pharmaceuticals is expected to merge with a wholly-owned subsidiary of Arsanis in an all-stock transaction. “X4 has pioneered the development of novel, oral drug candidates targeting pathways that have been demonstrated to improve immune cell trafficking and restore healthy immunity in genetically-driven rare diseases and lymphomas.

  • GlobeNewswire5 months ago

    Arsanis Reports Financial Results for Third Quarter 2018

    WALTHAM, Mass. and VIENNA, Austria, Nov. 09, 2018 -- Arsanis, Inc. (NASDAQ: ASNS), a clinical-stage biopharmaceutical company focused on applying monoclonal antibody (mAb).

  • Business Wire10 months ago

    INVESTOR ALERT: Investigation of Arsanis Announced by Holzer & Holzer

    Holzer & Holzer, LLC is investigating whether Arsanis, Inc. (“Arsanis” or the “Company”) (ASNS) complied with the federal securities laws. On June 28, 2018, Arsanis announced the discontinuation of its Phase 2 clinical trial of ASN100, a preventive drug for mechanically ventilated patients with a high risk of contracting pneumonia. Arsanis disclosed that an analysis completed by an independent drug review committee found that continuing the trial was “futile” because the target primary end-point likely would not be met upon completion. If you purchased Arsanis common stock and suffered a loss on that investment, you are encouraged to contact Corey D. Holzer, Esq.

  • Business Wire11 months ago

    Arsanis Reports Business Highlights and Financial Results for First Quarter 2018

    Arsanis, Inc. , a clinical-stage biopharmaceutical company focused on applying monoclonal antibody immunotherapies to address serious infectious diseases, today reported business highlights and financial results for the first quarter ended March 31, 2018.